Biotech Earnings: The 5 Numbers That Move Stocks

If you’re reading the EPS line on a biotech earnings report, you’re reading the wrong line. A biotech company can miss revenue by 30% and the stock goes up 15% because the pipeline readout is what matters. A big pharma can beat on EPS and the stock drops because guidance was cut.

Biotech earnings are different. Here are the 5 things that actually move the stock, in priority order.

Step 1: Pipeline updates (slide 8–12 of the deck)

The pipeline slide matters more than the income statement. Open the earnings presentation, not the press release. The presentation PDF has the data, the press release has the spin.

What to look for:

• Trial enrollment progress: Is the Phase 3 fully enrolled? On track? “Enrollment completion expected H2 2026” is vague. Check ClinicalTrials.gov for the actual status.
• Data readout timelines: Any delays? A readout that slips from “Q3 2026” to “H2 2026” in one quarter is a yellow flag. Two consecutive delays is a red flag.
• Discontinuations: What got killed? A company killing a Phase 2 program quietly in the pipeline appendix is not a cost-saving move. It’s a failed trial they don’t want to announce.
• New additions: What entered the clinic? New Phase 1 programs are noise unless the company has a platform that makes them relevant.

Real example: Pfizer (PFE) Q2 2026 earnings showed a pipeline cleanout in obesity: berobenatide stayed, other obesity programs were cut. That’s not cost discipline. That’s the company pruning programs that failed behind the scenes. Read the PFE Q2 earnings breakdown for the full story.

Step 2: Cash runway (the only number for pre-revenue biotechs)

For companies without a marketed drug, cash is everything. Revenue, EPS, and gross margin are irrelevant until they have a product.

Formula: (Cash + Cash equivalents + Short-term investments) ÷ (Net cash used in operating activities ÷ 3 months) = runway in months.

Find the numbers in the balance sheet and cash flow statement of the 10-Q, not the earnings press release. The press release is a marketing document. The 10-Q is the legal filing.

Thresholds:

• Under 12 months: dilution is coming. Assume a secondary offering within 90 days. Secondary offerings typically drop biotech stocks 20–30% on announcement.
• 12–18 months: tight. Management may be waiting for a catalyst to raise at a better price. Risk is real.
• Over 24 months: the company can survive a trial failure without immediate dilution.

Red flag: Check the shares outstanding count on the 10-Q cover page versus the prior quarter. If it increased by more than 5%, the company has been using an ATM facility (at-the-market offering) to quietly dilute shareholders between earnings reports. This is stealth dilution, and it doesn’t show up as a line item.

Step 3: Guidance revisions

For commercial-stage biotechs, revenue guidance cuts are the highest-impact earnings signal. A company that cuts full-year guidance by 10% typically sees the stock drop 10–20% within 24 hours. A company that raises guidance by 10% typically sees a 5–15% gain. The magnitude matters.

Real example: Merck (MRK) Q2 2026 cut profit guidance due to a $2.31/share charge tied to the Terns Pharmaceuticals acquisition. GAAP loss per share was $0.54, compared to earnings of $1.76 in Q2 2025. Non-GAAP loss was $0.13 per share. But the stock didn’t crater on that headline: the Terns charge was a one-time acquisition cost, not an operating problem. The market can distinguish between a pipeline investment and a business decline. See the MRK Q2 2026 earnings analysis.

What to check: Is the guidance cut a one-time charge (acquisition, impairment, restructuring) or an operating decline (competition, patent cliff, price erosion)? One-time charges often create buying opportunities. Operating declines don’t reverse in one quarter.

Step 4: R&D spend trajectory

Rising R&D is good if it’s funding late-stage trials that will read out within 12 months. Rising R&D into early-stage programs without catalysts in 18+ months is a red flag: the company is spending money on science, not on events that can move the stock.

What to check: Look at the R&D line versus the prior year quarter. Is the growth rate accelerating or decelerating? Decelerating R&D growth in a pre-revenue biotech often means the company is running low on cash and slowing trials to extend runway. That’s a red flag in disguise.

Real example: Novo Nordisk (NVO) took a DKK 6.3 billion non-cash impairment charge in Q2 2026, including DKK 4.0 billion for monlunabant. The drug was terminated, and the impairment flowed through the income statement as a one-time hit. The stock’s reaction depended entirely on whether investors believed the remaining pipeline could offset the loss. Read the NVO Q2 pipeline impairment breakdown.

Step 5: Conference call tone and non-answers

The Q&A with analysts after the prepared remarks is more important than the prepared remarks themselves. Management scripts the prepared remarks. They can’t script the Q&A.

What to listen for:

• Dodged questions: An analyst asks about enrollment delays and the CEO pivots to “we’re very excited about the opportunity.” That’s a dodge. Dodged questions on conference calls are red flags.
• Short answers to big questions: “Can you update us on the manufacturing facility inspection?” Answer: “We’re working with the FDA.” That 4-word answer should have been a 2-minute update. Something is wrong.
• Tone shifts: A CEO who was confident and detailed last quarter and is now vague and short is signaling bad news that hasn’t been disclosed yet.

Real example: Vertex (VRTX) Q2 2026 earnings call provided specific detail on the povetacicept PDUFA timeline (November 30, 2026). That level of specificity (an exact date, not a quarter) signals confidence. A company that won’t name a PDUFA month is worried about something. Read the VRTX Q2 2026 earnings coverage.

Common mistakes

Reading the EPS line first. Biotech earnings are about the pipeline, not the quarter. A GAAP miss driven by a one-time acquisition charge (like MRK’s Terns charge) means nothing for the business. A GAAP beat driven by cost-cutting with a quietly delayed Phase 3 trial is a sell signal.

Ignoring the 10-Q. The earnings press release is optional reading. The 10-Q is mandatory. It contains the detailed financials, risk factors, and legal proceedings that the press release omits. If something went wrong in the quarter, it’s in the 10-Q.

Treating non-GAAP as “real” earnings. Non-GAAP earnings exclude stock-based compensation, acquisition charges, and restructuring costs. For pre-revenue biotechs, stock-based compensation is often 20–40% of operating expenses. Ignoring it means you’re ignoring the dilution that funds the company.

Comparing a biotech’s earnings to a tech company’s earnings. A biotech with $0 revenue and a $500M market cap is not “overvalued.” The market is pricing the probability of a drug approval, not current earnings. Use the biotech valuation guide for the rNPV framework that actually applies.

Final checklist

• Pipeline slide reviewed: enrollment on track, no delays, no hidden discontinuations
• Cash runway calculated from 10-Q: over 18 months preferred
• Guidance revision analyzed: one-time charge or operating decline?
• R&D spend trajectory confirmed: funding late-stage trials, not early-stage science projects
• Conference call Q&A listened to: no dodged questions, specific answers to timeline questions
• 10-Q checked for risk factors and shares outstanding changes

For the full investing framework, start with how to invest in biotech stocks. For a real example of earnings driving a stock, see Gilead’s Q2 2026 earnings, where the base business surge masked acquisition charges.